Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
EXOZthis companyeXoZymes, Inc.	$4.21	-10×	26.89×	0×	-9.98×	-96.8%	0.0%	0.0%	0.0%	-269.6%	-203.1%	-7.3%	0.37×	0.2×	0×	2.51×	0.0%	1	-2.59	1	C-
ATOSAtossa Therapeutics, Inc.	$2.13	-2.19×	1.94×	0×	-1×	88.9%	0.0%	0.0%	0.0%	-88.4%	-94.4%	-39.1%	0×	1.19×	0×	5.53×	0.0%	1	-11.86	2	B-
CGTXCognition Therapeutics, Inc.	$0.73	-4.22×	2.87×	0×	-2.67×	-14.9%	0.0%	0.0%	0.0%	-68.5%	-136.9%	-25.0%	0.02×	1.56×	-3,676.85×	3.45×	0.0%	1	-0.97	2	C+
ESLAEstrella Immunopharma, Inc.	$0.50	-4.46×	-5.54×	0×	-4.29×	-94.4%	0.0%	0.0%	0.0%	126.0%	126.0%	-3.1%	0×	0.11×	0×	0.12×	0.0%	2	-52.49	2	C
GLSIGreenwich LifeSciences, Inc.	$16.25	-14.69×	805.09×	0×	-14.37×	-99.2%	0.0%	0.0%	0.0%	-5480.5%	-5505.9%	-3.5%	0×	0.32×	0×	1.06×	0.0%	1	2.27	1	D+
ONCYOncolytics Biotech Inc.	$0.45	-2.92×	-22.05×	0×	-3.79×	-94.9%	0.0%	0.0%	0.0%	551.7%	-1250.6%	-17.5%	-0.15×	0.22×	0×	1.12×	0.0%	1	-95.51	2	C
Peer median	—	-4.22×	1.94×	0×	-3.79×	-94.4%	0.0%	0.0%	0.0%	-68.5%	-136.9%	-17.5%	0×	0.32×	0×	1.12×	0.0%	1	-11.86	2	—